Can rivaroxaban be a drug of choice for treating heparin-induced thrombocytopenia in a patient with pulmonary thromboembolism?
Open Access
- 1 January 2017
- journal article
- case report
- Published by Kare Publishing in The Anatolian Journal of Cardiology
- Vol. 18 (1) , 77-79
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Rivaroxaban for treatment of suspected or confirmed heparin‐induced thrombocytopenia studyJournal of Thrombosis and Haemostasis, 2016
- Treatment and Prevention of Heparin-Induced ThrombocytopeniaChest, 2012
- Heparin Induced Thrombocytopenia: Case Presentation and ReviewJournal of Clinical Medicine Research, 2012
- Rivaroxaban – an oral, direct Factor Xa inhibitor – has potential for the management of patients with heparin‐induced thrombocytopeniaBritish Journal of Haematology, 2008
- Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin‐induced thrombocytopenia in two clinical settingsJournal of Thrombosis and Haemostasis, 2006
- Heparin-induced thrombocytopenia: an updateThrombosis Journal, 2005
- Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopeniaBlood, 2005